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INTRODUCTION
The development of a heart-lung machine, also called
cardio-pulmonary bypass (CPB), in the fifties was a milestone
for cardiac surgery. The extracorporeal circulation technique
allowed very complex heart operations like congenital heart
defects (1). However, possible negative effects of CPB on the
bypassed organs (heart and lung) should not be neglected. Heart
and lung are not or insufficiently perfused during the whole time
of bypass (which could be up to 2 hours or more depending on
the kind of heart operation) and thus are subjected to ischemia
and reperfusion injury. Although blood supply of the lung is
maintained via the Vasa privata, i.e. the bronchial arteries, which
are supplied with blood by the heart-lung machine, it has been
demonstrated that during CPB blood flow is low in these vessels
and not sufficient to avoid ischemia (2). Moreover, typically
lung ventilation is reduced or even discontinued during bypass
which might promote the occurrence of atelectasis, pulmonary
vasoconstriction (via Euler-Liljestrand-reflex) and interstitial
pulmonary oedema (3). Thus, postoperative lung dysfunction is
not uncommon and has serious implications on patient recovery.
Furthermore, the flow profile of CPB has to be taken into
consideration: traditionally CPB was developed with a non-
pulsatile flow and this flow regimen is the most common
procedure today. However, a more physiological pulsatile flow
might be of advantage for organ integration. Thus,
hypothetically pulsatile flow may lead to a better mixture of
blood components and might enable each red blood cell to come
into contact with the vessel wall thereby improving gas
exchange in peripheral tissue so that finally this might reduce
organ damage during pulsatile CPB. However, in a recent study
of 37 patients beneficial effects of pulsatile CPB on lung
function could not be detected (4)
At the same period of time when CPB was introduced in heart
surgery a new class of antibiotics were detected: the tetracyclines
with aureomycin (which is chlortetracycline) being the first of this
class (5). Tetracyclines belong to the broad spectrum antibiotics
and up to now several synthetic and semi-synthetic derivatives
have been found. Minocycline, which has a long half-life was
introduced in 1966 and still is in use nowadays (6). In addition to
its anti-microbial activity it has also some interesting ‘side-
effects’: neuroprotective properties in neurodegenerative diseases
like Morbus Huntington or Morbus Parkinson and anti-
inflammatory as well as anti-apoptotic effects via attenuation of
pro-inflammatory cytokines like TNF-α and inhibition of caspase-
dependent or caspase independent pathways (7, 8). These anti-
inflammatory properties might be advantageous in CPB since it is
known that CPB induces significant systemic inflammatory
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Since the invention of the heart-lung machine paediatric cardiac surgery developed rapidly. For correction of complex
cardiac malformations the application of a cardio-pulmonary bypass (CPB) has become indispensable but possible negative
effects of this technique should not be neglected. Especially, both bypassed organs i.e. heart and lung are not perfused
during the procedure and therefore are threatened by ischemia and reperfusion injury. Additionally, CPB was developed
with a non-pulsatile flow but there are clinical observations that pulsatile flow might be superior with improved patient
outcomes. Thus, the aim of our study was to evaluate the effect of CPB on lung structure and to assess whether different
flow modalities (pulsatile vs. non-pulsatile flow) or application of the antibiotic minocycline might be advantageous. Thirty
five piglets of four weeks age were examined and divided into five experimental groups: control (no CPB) without or with
minocycline, CPB (non-pulsatile flow) without or with minocycline and CPB with pulsatile flow. CPB was performed for
90 min followed by a 120 min reperfusion and recovery phase. Thereafter, adenosine triphosphate-content of lung biopsies
and histology was carried out. We found that CPB was associated with a significant thickening of alveolar wall
accompanied by an infiltration of neutrophil leucocytes. Moreover, markers for hypoxia, apoptosis, nitrosative stress,
inflammation and DNA damage were significantly elevated after CPB. These cellular damages could be partially inhibited
by minocycline or pulsatile flow. Both, minocycline and pulsatile flow attenuate lung damage after CPB.
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responses (9). This inflammatory reaction is presumably triggered
by the contact of blood components with external surfaces of the
CPB (oxygenator, tubes, coupling pieces etc.) (10). Moreover,
besides inflammation a transient decline of blood pressure during
CPB (that might occur during manipulation of the large vessels)
results in reduced organ perfusion and might cause organ
malfunction which impairs patient outcome.
In summary, lung protection during cardiac operations is still
a matter of debate and protective measures have to be found to
better preserve lung function.
Thus, the aim of our study was to evaluate in a clinical
setting of CPB the influence of the heart-lung machine on the
lung and to assess histologically which kind of injury might
occur during this procedure. Moreover, the anti-apoptotic and
anti-inflammatory drug minocycline or a pulsatile flow during
CPB was investigated. As an experimental model piglets of four
weeks age were used.
MATERIAL AND METHODS
Animals
The following procedures were reviewed and approved by
the Animal Care Committee of the German Regional Council
Leipzig which ensured humane treatment of all animals as
indicated by the ‘Guide for the Care and Use of Laboratory
Animals’ published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996).
For our experiments we used 35 Angeln Saddleback piglets
of 4 weeks age weighting between 8 and 12 kg. The piglets were
divided in 5 groups a 7 animals:
1) control group without minocycline;
2) control group with minocycline;
3) non-pulsatile CPB group without minocycline;
4) non-pulsatile CPB group with minocycline;
5) pulsatile CPB (without minocycline).
Experimental procedure
The operation procedure was carried out as described earlier
by our group (11). In brief, all animals received the same pre-
medication (atropine, midazolam, ketamine), they were
intubated and mechanically ventilated using a Cato anesthesia
apparatus (Dragerwerk, Lubeck, Germany). Settings of the
mechanical ventilator, for all piglets, were as follows: 50% air
and 50% O2 = FiO2 50; tidal volume 10 ml/kg body weight,
respiratory rate 20 – 30/minute, PEEP (positive end-expiratory
pressure) 2 mbar, maximum pressure 25 mbar, ratio
inspiration/expiration 1:2. During CPB the piglets were
continuously ventilated with a tidal volume of 5 ml/kg body
weight, a respiratory rate of 10/minute and PEEP 2 mbar in order
to avoid formation of atelectasis (12). In contrast, for the whole
experimental procedure control piglets were ventilated with the
ventilator settings described above (this means no reduction of
tidal volume or respiratory rate).
Anaesthesia was carried out using isoflurane and sufentanil-
dihydrogenecitrate. All piglets were thoracotomized but only
animals of the three CPB groups were connected to the heart lung
machine, which consisted of a roller pump (SIII Stoeckert,
Freiburg, Germany), a membrane oxygenator (Dideco, Mirandola,
Italy) and a pediatric tubing set (Sorin, Munchen, Germany).
Priming volume was 200 ml whole blood supplemented with
heparin to achieve an activated clotting time of > 400 s. Arterial
line was inserted in the ascending aorta. Venous line was
connected to both superior and inferior caval vein via the right
atrial auriculum. For the duration of pulsatile and non-pulsatile
bypass piglets were perfused with a flow rate of 100 ml/kg/min
using a roller pump (SIII Stoeckert, Freiburg, Germany), which
can be switched between a laminar flow and a pulsatile flow. For
the pulsatile CPB pulsation was set to 100 beats/min, pump base
flow was 30%, pulsatile flow was 70% and pump runtime was
50% according to Alka-Bozkaya et al. and as published earlier
(13, 14). Resulting peak pressure in the femoral artery was 78 ± 6
mmHg and diastolic pressure was 59 ± 5 mmHg.
Cardioplegia was induced by application of cold Custodiol
solution (Dr. Franz Kohler Chemie GmbH, Bensheim,
Germany), the aorta was clamped, CPB was started and the
piglets were cooled to 28°C for 60 minutes. Thereafter, the
piglets, still connected to the CPB, were re-warmed again for
another 30 minutes. Subsequently, after reaching, for that
species, a normal core body temperature of 38 – 39°C the aortic
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ATP, adenosine triphosphate; CPB, cardio-pulmonary bypass; FiO2 fraction of inspired oxygen; MAP, mean arterial pressure; mino,
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*P < 0.05 versus time 0, §P < 0.05 versus CPB, $P < 0.05 versus control.
Table 1. Functional parameters.
thereby allowing the heart to take over body circulation. At time
120 minutes the animals were disconnected from CPB, but not
de-cannulated, if necessary circulation was supported with
catecholamines to maintain an arterial mean pressure above 50
mmHg (cumulative dose was 0.004 mg/kg norepinephrine and
0.03 mg/kg epinephrine, with no difference among the CPB
groups). Moreover, oxygen saturation, pH, lactate, blood gases
as well as central venous pressure were measured and if
necessary therapeutic interventions were performed. After
disconnection from CPB the piglets recovered for additional 90
minutes. Post-CPB ventilation was carried out with the
following settings: FiO2 50; tidal volume 10 ml/kg body weight,
respiratory rate 20 – 30/minute, PEEP 2 mbar, maximum
pressure 25 mbar and ratio inspiration/expiration 1:2.
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Fig. 1. HE-staining of alveoli. Bar
graphs depict alveolar septa thickness
(white bars, left y-axis) and number of
neutrophil granulocytes (grey bars,
right y-axis). Original images below
show thickness of alveolar septa
marked with a black arrow.
In the experimental groups receiving drug 4 mg/kg body
weight minocycline was administered 30 minutes before start of
CPB or start of control and a second dose of 2 mg/kg body
weight after disconnection from CPB or for the controls at the
appropriate time points. Minocycline was dissolved in 10 ml
aqua ad injectionem which was also used as solvent control in
the experimental groups without minocycline.
The following time scale was used:
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Fig. 2A. HIF1α-staining of alveoli and
bronchial epithelium. Bar graphs depict
the number of positive nuclei (in %).
Original images of alveoli are depicted
below; black arrows indicate HIF1α
positive cells, stained in red. Significant
differences versus control are indicated
by asterisks, significant differences
versus non-pulsatile CPB by a section
sign (P < 0.05).
- time –30: administration of minocycline 4 mg/kg and
solvent respectively;
- time 0: clamping of the aorta and start of CPB or start of
controls. The animals of CPB-groups were cooled to 28°C, the
control animals remained normothermic.
After 60 minutes the cooled piglets, still connected to the
CPB, were rewarmed to 38 – 39°C.
- time 90: opening of aortic cross clamp and reperfusion.
During the 30 minutes timeframe piglets were weaned from the
CPB;
- time 120: disconnection of CPB and application of
minocycline 2 mg/kg and solvent respectively;
- time 210: end of recovery and also end of the controls.
During CPB volatile anaesthesia with isoflurane was
switched to propofol and was re-administered during
reperfusion. The same anaesthesia pattern was performed in both
groups of control piglets.
At the end of experiments lung biopsies were taken and were
either fixed in neutral buffered 4% formalin solution for
histological examination or snap frozen in liquid nitrogen for
adenosine triphosphate (ATP) analysis.
Adenosine triphosphate-measurement by high-pressure liquid
chromatography (HPLC)
Tissue ATP levels were determined by HPLC (high-pressure
liquid chromatography) as previously described (15). In brief,
lung samples were mixed with cold perchloric acid and
precipitated with KOH. Subsequently, probes were centrifuged
and 20 µL of each supernatant was injected at a flow of 1 mL/min
onto a pre-equilibrated RP18 column (Lichrocart, Merck,
Darmstadt, Germany). ATP was detected using an UV-detector
(PDA Detector 2800) and a HPLC-apparatus (both Knauer Berlin,
Germany). ATP-peaks were measured at 254 nm. For calibration
ATP-standards were injected during each run.
Each sample (standard and probe) was injected three times,
and the concentration was determined as the mean of these three
injections.
Lung function
Lung function was measured in vivo by assessing paO2 (arterial
oxygen pressure), FiO2 (fraction of inspired oxygen), compliance,
paCO2 (arterial carbon dioxide pressure) and blood pH.
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Fig. 2B. HIF1α-staining of bronchial
epithelium. Black arrows indicate
HIF1α positive cells.
Dynamic lung compliance was calculated according to
Slottosch et al. (16), using the following formula:
Compliance = tidal volume/PIP – PEEP
where PIP - peak inspiratory pressure, PEEP - positive end-
expiratory pressure.
Histology
Preparation and staining of the samples were done as
previously published (15). Briefly, lung samples embedded in
paraffin were sectioned in 2 µm slices. Thereafter, the slices
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Fig. 3A. cC3-staining of alveoli and
bronchial epithelium. Bar graphs depict
the number of positive nuclei (in %).
Original images of alveoli are depicted
below; black arrows indicate cC3
positive cells, stained in red. Significant
differences versus control are indicated
by asterisks (P < 0.05).
were de-waxed and hematoxylin-eosin (HE) staining or
immunostainings were carried out.
All specimens were viewed and analysed using the
Axioimager M1 from Zeiss and the Zen Pro 2012 software
(Jena, Germany). Pictures were randomly taken at 400 ×
magnification and 15 pictures per piglet were evaluated by a
blinded observer.
Hematoxylin-eosin (HE) staining
HE staining was carried out following standard protocols.
For each piglet more than 60 alveoli were analysed and the
thickness of alveolar wall was measured as described earlier
(11). Moreover, neutrophil granulocytes were counted and
related to the number of alveoli.
Immunohistology
Lung specimens were stained for markers of hypoxia,
inflammation, apoptosis, and nitrosative stress. Moreover, the
amount of apoptotic cells was also evaluated.
Hypoxia-inducible factor 1alpha (HIF1α)
It is known that the transcription factor HIF1α translocates
from cell cytoplasm into the nucleus as a response to decreases
in ambient oxygen (17). We evaluated the amount of cell nuclei
positive for HIF1α in the alveoli and bronchial epithelium.
Therefore, lung specimen were treated with 2% bovine serum
albumin (BSA) to reduce unspecific background and stained
with rabbit anti-HIF1α primary antibody (1:100, Santa Cruz,
Heidelberg, Germany) at 4°C over night. After several washing
steps secondary horseradish peroxidase-labelled antibody was
applied (1:200, 1 hour, room temperature) and visualized using
the red chromogen AEC (3-amino-9-ethylcarbazol, DAKO,
Hamburg, Germany). Nuclei were counterstained with
hematoxylin. The number of HIF1α positive nuclei (red) were
counted and related to the number of negative nuclei (blue).
Apoptosis-inducing factor (AIF) and poly-ADP-ribose (PAR)
PAR stimulates the mitochondrial release of AIF, a transcription
factor which triggers the caspase-independent pathway of apoptosis
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Fig. 3B. cC3-staining of bronchial
epithelium. Black arrows indicate cC3
positive cells.
(18, 19). PAR itself is formed during DNArepair processes by PAR-
polymerase (PARP) and might serve as a marker for DNA strand
breaks. Thus, in our specimen AIF was stained using rabbit anti-AIF
primary antibody (1:50, Santa Cruz, Heidelberg, Germany) and
PAR using mouse anti-PAR primary antibody (1:300, Bio-Rad,
Munchen, Germany) according to a previously published protocol
(15). After washing the appropriate secondary antibodies (1:200)
were applied and detection was carried out using AEC. Again
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Fig. 4A. AIF-staining of alveoli and
bronchial epithelium. Bar graphs depict
the number of positive nuclei (in %).
Original images of alveoli are depicted
below; black arrows indicate AIF
positive cells, stained in red. Significant
differences versus control are indicated
by asterisks (P < 0.05).
counterstaining of nuclei was done with hematoxylin. Evaluation
was performed as described for HIF1α.
Cleaved caspase-3 (cC3)
Caspases are also involved in the programmed cell death. The
caspase cascade is initiated by various intrinsic and extrinsic
stimuli. Once activated, executioner caspases like caspase-3 start
the process of apoptosis (20). As the cleaved form of caspase-3 is
the activated form we used rabbit anti cleaved caspase-3 antibody
(1:200, New England Biolabs, Frankfurt, Germany) in our lung
samples. Detection of positive cell nuclei was carried out as
described for HIF1α.
Nitrotyrosine staining
Reactive nitrogen species like peroxynitrit which occur
during reperfusion are able to nitrosylate tyrosine residues of
proteins. The resulting nitrotyrosines might be used as a
biomarker for nitrosative stress (21). Thus, we determined the
amount of nitrotyrosine-positive cells in our samples using a
rabbit anti-nitrotyrosine antibody (1:500, Millipore, Darmstadt,
Germany). Detection was carried out as described above and the
number of nitrotyrosine positive cells (red) was evaluated in
relation to the unstained cells.
Tumor necrosis factor alpha (TNF-α)
CPB may initiate an inflammatory reaction and enhance TNF-
α release from neutrophil granulocytes (22). Thus, we also
investigated TNF-α in our lung probes. We used a rabbit anti-TNF-
α antibody (1:100, Santa Cruz, Heidelberg, Germany). Detection
was carried out as described for the nitrotyrosine staining.
In situ detection of apoptosis
In addition to the investigation of AIF as an early step in
apoptosis, we also aimed to detect apoptotic cells using the ‘In situ
Apoptosis Detection Kit’ from Abcam (Berlin, Germany).
Conduction of the experimental work was carried out according to
the manufacturer’s instruction. Briefly, specimen were permeabilised
with proteinase K, labelled with biotin-labelled deoxynucleotides by
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Fig. 4B. AIF-staining of bronchial
epithelium. Black arrows indicate AIF
positive cells.
TdT (terminal deoxynucleotidyl transferase) and finally detected
with DAB (diaminobenzimide). Counterstaining was done with
methyl green. For evaluation positive that is apoptotic cell nuclei
(brown) were related to negative nuclei (green).
Statistical analysis
For statistical analysis, analysis of variance was
performed using the software Systat for Windows, version 11
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Fig. 5. Apoptosis. Bar graphs depict the
number of apoptotic cells (in %).
Original images of alveoli are displayed
below, black arrows indicate apoptotic
cells, stained in brown.
(Systat Inc., Evanston, IL, USA), and if ANOVA indicated
significant differences (P < 0.05), post-hoc Tukey´s HSD test
was carried out.
All data are given as means ± S.E.M. of n = 7 experiments.
RESULTS
At the beginning of the experiments all piglets had the same
functional status (heart rate, ejection fraction, blood pressure,
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Fig. 6A. PAR-staining of alveoli and
bronchial epithelium. Bar graphs depict
the number of positive nuclei (in %).
Original images of alveoli are depicted
below; black arrows indicate PAR
positive cells, stained in red. Significant
differences versus control are indicated
by asterisks, significant differences
versus non-pulsatile CPB by a section
sign (P < 0.05).
central venous pressure etc.) and these parameters were controlled
and kept within the physiological range during the experiment.
In our clinical setting of CPB all piglets were successfully
weaned from CPB. During recovery some of them transiently
needed inotropic support. However, at the end of the recovery
period inotropic support could be terminated due to stable cardiac
function. Mean arterial pressure was not different between all
experimental groups (Table 1). Lactate levels were highest in the
CPB groups with no differences among them i.e. pulsatile flow or
minocycline had no influence on blood lactate concentration. Lung
ATP content significantly decreased in the non-pulsatile CPB group,
whereas supplementation of minocycline during CPB or pulsatile
flow significantly prevented from ATP decline (Table 1). PaO2/FiO2
as well as lung compliance significantly decreased during the entire
experiment (i.e. PaO2/FiO2 and compliance at time 210 was lower
compared to time 0) without differences between the 5 experimental
groups. paCO2 also was not significantly altered.
Hematoxylin-eosin staining
HE staining of alveoli revealed a significant increase in
alveolar wall thickness in the CPB group. Pulsatile flow had no
influence on alveolar septa width whereas addition of
minocycline led to a reduction in wall thickness to control levels
(Fig. 1, white bars). Additionally, CPB enhanced the number of
alveolar neutrophil granulocytes, which could be reduced by
minocycline but not by pulsatile flow (Fig. 1, grey bars).
Immunohistology
Alveolar translocation of HIF1α was significantly increased
during non-pulsatile CPB as could be estimated from the
enhanced number of HIF1α positive cell nuclei. Minocycline but
not pulsatile flow significantly prevented nuclear HIF1α
accumulation in alveolar epithelium (Fig. 2A, white bars). As
alveoli, bronchial epithelium also showed significant increases
in HIF1α within all CPB groups when compared to the control
group (Fig. 2A, grey bars). In contrast to alveoli, in bronchial
epithelium enhanced nuclear HIF1α could not be decreased
neither by minocycline nor by pulsatile flow (Fig. 2A, gray bars
and Fig. 2B).
Examination of cC3 showed a rise in the number of positive
cell nuclei within the alveolar wall in all three CPB-groups
without differences among them i.e. minocycline or pulsatile
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Fig. 6B. PAR-staining of bronchial
epithelium. Black arrows indicate PAR
positive cells.
flow did not reduce elevated cC3 (Fig. 3A, white bars). In
bronchial epithelium the amount of cC3 positive cell nuclei was
generally higher compared to alveolar epithelium. In contrast to
alveoli, in bronchial epithelium CPB did not enhance cC3 and no
differences in cC3 within the 5 experimental groups could be
detected (Fig. 3A, grey bars and Fig. 3B).
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Fig. 7A. Nitrotyrosine-staining of
alveoli and bronchial epithelium. Bar
graphs depict the number of positive
cells (in %). Original images of alveoli
are depicted below; black arrows
indicate nitrotyrosine (NT) positive
cells, stained in red. Significant
differences versus control are indicated
by asterisks, significant differences
versus non-pulsatile CPB by a section
sign (P < 0.05).
AIF evaluation revealed that CPB increased nuclear AIF.
However, neither minocycline nor pulsatile flow during CPB
were able to decrease enhanced nuclear AIF in the alveoli and
bronchial epithelium (Fig. 4A and 4B).
Furthermore, we also examined the number of apoptotic cells
using the In Situ Apoptosis Detection Kit from Abcam.
Interestingly, the number of cells undergoing apoptosis was about 1-
2% and was not different among our 5 experimental groups (Fig. 5).
CPB led to a significant formation of PAR in both alveolar
and bronchial epithelium. It is known from cell culture
experiments that minocycline can inhibit PARP thereby
inhibiting PAR formation (23). Accordingly, we saw a lowering
effect of minocycline on elevated PAR production during non-
pulsatile CPB in alveolar cells (Fig. 6A, white bars). However,
in bronchial cells this effect of minocycline was almost absent.
Similarly, pulsatile flow diminished the number of PAR positive
cells in the alveoli but not in bronchial epithelium (Fig. 6A grey
bars and Fig. 6B). However, in bronchial epithelium the
preventive effect of pulsatile flow was at the border of
significance.
Non-pulsatile CPB significantly increased nitrotyrosine
formation in both alveoli and bronchial epithelium. This raise in
nitrotyrosine positive cells was diminished by minocycline and
by pulsatile flow in both cell types (Fig. 7A and Fig. 7B).
TNF-α levels are enhanced during CPB which was also
shown in our study: we could detect significantly increased
TNF-α positivity in cells of the alveoli and in bronchial
epithelium. Minocycline and pulsatile flow both reduced the
number of cells with elevated TNF-α within the alveoli (Fig. 8A,
white bars). Bronchial epithelium showed the highest increases
of TNF-α during CPB which was significantly attenuated by
minocycline application and only slightly by pulsatile flow (Fig.
8A grey bars and Fig. 8B).
DISCUSSION
In our study we could demonstrate that non-pulsatile CPB
leads to impaired lung parameters such as decreased tissue ATP-
levels, structural changes and inflammation (as became evident
by enhanced alveolar wall thickening, by the elevated number
of neutrophil granulocytes and elevated TNF-α). Moreover, it
was shown that markers of hypoxia, nitrosative stress and
apoptosis were increased in both the alveolar wall and bronchial
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Fig. 7B. Nitrotyrosine-staining of
bronchial epithelium. Black arrows
indicate nitrotyrosine positive cells.
epithelium. Minocycline and pulsatile flow significantly
attenuated this lung injury in our experimental model.
Interestingly, independent of CPB, lung compliance as well as
paO2/FiO2 were lower at the end of experiment compared to
baseline, which might be due to surgical traumata and/or
mechanical ventilation. However, there was no CO2 retention.
Thus at the end of the experiment we found a discrepancy
between only slight functional changes but significant and large
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Fig. 8A. TNF-α-staining of alveoli and
bronchial epithelium. Bar graphs depict
the number of positive cells (in %).
Original images of alveoli are depicted
below; black arrows indicate TNF-α
positive cells, stained in red. Significant
differences versus control are indicated
by asterisks, significant differences
versus non-pulsatile CPB by a section
sign (P < 0.05).
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biochemical alterations. This is however very typical for the
clinical situation, when the patient normally leaves the
operation theatre with good blood gases but subsequently runs
into pulmonary dysfunction within the following 48 hours.
Thus, the histochemical data may indicate what functionally
may occur later.
Several aspects need to be discussed: a) the impairing effect
of CPB on the lung b) the protective effects of minocycline and
pulsatile flow and c) the differences in the effects on alveolar
versus bronchial epithelium.
a) During CPB the lung is not perfused (except a rest flow
via Vasa privata) and as a consequence ATP content decreased
nearly to zero, thus demonstrating the existence of ischemia
despite ventilation. Interestingly, HIF1α was elevated, which
may indicate that intracellularly metabolism was hypoxic
although minimal ventilation was maintained and bronchial
arteries were perfused via the CPB. Pathophysiologically, this
situation with continued ventilation but reduced blood flow
should lead to the production of free radicals which might impair
DNA integrity. According to this theory, nitrotyrosine was
elevated which means that increased levels of nitric oxide have
been released (as a consequence of ischemia, presumably) and
reacted with cellular proteins. Free radicals also can cause strand
breaks of DNA which activate PARP repair mechanism (24).
This also could be demonstrated in our data as the product of
PARP, i.e. PAR was elevated in CPB. PAR production together
with lack of ATP induces AIF release from mitochondria (25)
and AIF translocation into the nucleus, which clearly could be
seen in our study. Furthermore, the process leading to AIF
release from mitochondria together with DNA-damage will
finally activate caspase 3 and accordingly we also observed
increased cleavage of caspase 3. The time course of our
experiments, however, was probably too short to allow complete
development of apoptosis (Fig. 8); this can be explained by the
well-known fact that the development of apoptosis following
caspase 3 activation and AIF translocation needs about > 12
hours (26). Taken together, our data show an ischemic damage in
the lung during CPB leading to the initiation of apoptosis.
However, only the early first steps of apoptosis induction (cC3,
AIF, PAR) could be observed due to the 4 hours time frame of
the experiments, so that it is not possible to estimate the number
of cells finally undergoing apoptosis.
Fig. 8B. TNF-α-staining of bronchial
epithelium. Black arrows indicate TNF-α
positive cells.
b) Minocycline according to the data presented here
prevented from loss of ATP, production of PAR, thickening of
alveolar membrane, granulocyte accumulation, nitrotyrosine
formation and increased TNF-α expression. It is known that
minocycline can act as a radical scavenger (27) and can reduce
nitrosylation (28). Thus, it should lead to less 3-nitrotyrosine
formation as was demonstrated in our study and to reduced
DNA damage, which should result in diminished PAR-
formation, which also could be shown in our study. The
reduced PARP activity should theoretically lead to less ATP
consumption, which is in good accordance with our data
demonstrating preservation of ATP in CPB with minocycline.
Besides this, minocycline reduced TNF-α release and alveolar
granulocyte accumulation, which is in good accordance with
previous observations of anti-inflammatory effects of the drug
(7, 29). TNF-α release and granulocyte accumulation may be
part of an inflammatory lung reaction, which has been
observed in several animal models and which has been
described as ventilator induced lung injury (30, 31).
Pulsatile flow also protected against CPB-associated
impairment, preserving ATP, reducing PAR and nitrotyrosine
formation and -to a lower extent than minocycline- attenuating
TNF-α release. However, granulocyte accumulation and
alveolar thickening were not prevented. Thus, the protective
effects of pulsatile flow are present but do not reach the effects
of minocycline. It may be assumed that pulsatile flow leads to
better mixing of the cellular and non-cellular phase of the
blood so that oxygen delivery to the cells may be improved,
thus reducing ischemic impairment.
c) An interesting aspect of the study is that alveolar
epithelium was less reactive to CPB-associated injury than
bronchial epithelium as far as HIF1α and AIF are concerned. It
might be that due to cilial activity and secretory action
bronchial epithelium consumes more oxygen and thus is more
prone to ischemic damage. On the other hand effects of
minocycline or pulsatile flow treatment were more prominent in
the alveoli which might be due to the fact, that the distance
between alveolar cells and erythrocytes/blood is lower than in
bronchiolar epithelium. In contrast, the inflammatory response
with regard to TNF-α was more prominent in the bronchial
epithelium, which may indicate that bronchial epithelium is
more prone to inflammation, i.e. has a higher inflammatory
responsivity. This effect, which should be independent from
circulation, accordingly could not be influenced by pulsatility
of flow but by the anti-inflammatory action of the drug
minocycline.
Taken together, this study shows that CPB can damage the
lung, which helps to explain why patients often suffer from
pulmonary dysfunction after CPB. Moreover, two strategies
could be identified which have the potential to prevent from lung
injury in CPB. Clinical studies are now needed to clarify if this
holds also true in humans.
Abbreviations: AEC, 3-amino-9-ethylcarbazol; AIF,
apoptosis-inducing factor; ATP, adenosine triphosphate; BSA,
bovine serum albumin; cC3, cleaved caspase-3; DAB,
diaminobenzimide; CPB, cardio-pulmonary bypass; HE,
hematoxylin-eosin; HIF1α, hypoxia-inducible factor-1alpha;
HPLC, high-pressure liquid chromatography; PAR, poly-
ADP-ribose; paO2, arterial oxygen pressure; paCO2, arterial
carbon dioxide pressure; PEEP, positive end-expiratory
pressure; PIP, peak inspiratory pressure; TdT, terminal
deoxynucleotidyl transferase; TNF-α, tumor necrosis factor
alpha
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